Pharmaceutical Business Review Latest NewsLatest news from Pharmaceutical Business ReviewEniva's nutraceutical found effective in human cell study- July 7, 2008 The Eniva Research Group has reported results from laboratory testing by the Linus Pauling Micronutrient Research Institute at Oregon State University which demonstrated the Eniva health supplement Vibe possessed DNA protective anti-mutagenic activity for human cells.http://www.pharmaceutical-business-review.com/article_news.asp?guid=A87B9388-DFA0-4BB8-8D3... LinkMed to acquire Olerup SSP- July 7, 2008 LinkMed, a private equity company in the life science sector, has said that it is acquiring 100% of the shares in Sweden-based biotechnology company Olerup SSP. The value of the acquisition is SEK216 million.http://www.pharmaceutical-business-review.com/article_news.asp?guid=89985A4F-1FB4-47AB-ACF... ABL signs patent licensing agreement with Viralliance- July 7, 2008 ABL Patent Licensing Technologies, a subsidiary of Advanced Biological Laboratories, has entered into a patent licensing agreement with Viralliance.http://www.pharmaceutical-business-review.com/article_news.asp?guid=885D1C01-A99F-4AA5-B20... Bio-Bridge Science secures $2.77 million in financing- July 4, 2008 US based biotechnology company Bio-Bridge Science has closed a $2.77 million private placement of its investment units.http://www.pharmaceutical-business-review.com/article_news.asp?guid=3BB31ED2-2715-43E3-898... Bentley announces cash purchase price adjustment- July 4, 2008 Bentley Pharmaceuticals has announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, Cpex Pharmaceuticals.http://www.pharmaceutical-business-review.com/article_news.asp?guid=6771AFE6-5678-43E4-A38... ADI wins SBIR Phase II grant to commercialize novel antigens- July 4, 2008 Antigen Discovery has received a Phase II SBIR from the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources.http://www.pharmaceutical-business-review.com/article_news.asp?guid=A5EA14AD-4167-4A1E-B4A... Senesco selects VGXI to produce Factor 5A plasmid- July 4, 2008 Senesco Technologies has contracted with VGXI to supply the plasmid portion of its combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.http://www.pharmaceutical-business-review.com/article_news.asp?guid=49F2A90E-A275-4C99-9DE... APP wins approval for additional dosages of generic Kytril injection- July 4, 2008 APP Pharmaceuticals has received final approvals from the FDA of its abbreviated new drug applications for Granisetron hydrochloride injection, 1mgml, 1ml single dose, and 1mgml, 4ml multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril injection.http://www.pharmaceutical-business-review.com/article_news.asp?guid=0938BBB2-0CE4-47F4-878... Bioheart names new CEO- July 4, 2008 Bioheart has appointed Howard Leonhardt, co-founder, chairman of the board and chief technology officer of the company as its new CEO.http://www.pharmaceutical-business-review.com/article_news.asp?guid=DE1F476B-2913-434B-B13... Senesco signs supply agreement with Polyplus-transfection- July 4, 2008 Senesco Technologies has contracted with France-based Polyplus-transfection to supply Polyplus's 'in vivo-jetPEI' for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.http://www.pharmaceutical-business-review.com/article_news.asp?guid=20860828-C997-4F58-990... |